Clover Biopharmaceuticals coronavirus vaccine status <br /> <br />Clover Biopharmaceuticals has said the first participants have been dosed with its COVID-19 S-Trimer sub-unit vaccine candidate (SCB-2019) in the Phase 1 first-in-human study. <br /> <br />The development makes it the sixth Chinese developer of a potential Covid-19 vaccine to move into human trials. <br /> <br />Clover’s trial, which is enrolling about 150 adult and elderly patients, will evaluate two different boosters, or adjuvants, from Britain’s GSK and US-based Dynavax in combination with its candidate shot, SCB-2019, Reuters quoted the Chinese company as saying. <br /> <br />The study is being conducted at Linear Clinical Research in Perth, Australia. The trial and Clover’s COVID-19 vaccine program is being supported by the funding and collaboration with the Coalition for Epidemic Preparedness Innovations (CEPI). <br /> <br />Clover said initial safety data from its study was expected in August this year, and it would aim to start broader studies by year end. Its
